Curemark   Report issue

For profit Phase 3
Founded: Rye NY United States (2004)
Status: Left NME R&D (2020)

Organization Overview

First Clinical Trial
2009
NCT00881452
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

cm-at (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Autistic Disorder (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 1